Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study

Elagolix sodium salt is the first marketed orally active non-peptide gonadotropin-releasing hormone receptor antagonist (GnRHR-ant) for the management of hormone dependent diseases, such as endometriosis and uterine fibroids. Despite its presence on the market since 2018, a thorough NMR analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciceri, Samuele, Colombo, Diego, Fassi, Enrico M. A., Ferraboschi, Patrizia, Grazioso, Giovanni, Grisenti, Paride, Iannone, Marco, Castellano, Carlo, Meneghetti, Fiorella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180344/
https://www.ncbi.nlm.nih.gov/pubmed/37175271
http://dx.doi.org/10.3390/molecules28093861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180344/
https://www.ncbi.nlm.nih.gov/pubmed/37175271
http://dx.doi.org/10.3390/molecules28093861

Ejemplares similares